Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.metropolisindia.com | |
Market Cap | 6,628.45 Cr. | |
Enterprise Value(EV) | 6,675.76 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 30.22 | Trailing Twelve Months Ending 2022-09 |
Price-Earning Ratio (PE) | 42.83 | Trailing Twelve Months Ending 2022-09 |
Industry PE | 46.72 | Trailing Twelve Months Ending 2022-09 |
Book Value / Share | 185.24 | Trailing Twelve Months Ending 2022-09 |
Price to Book Value | 6.99 | Calculated using Price: 1,294.35 |
Dividend Yield | 0.62 | Period Ending 2022-03 |
No. of Shares Subscribed | 5.12 Cr. | 51,210,664 Shares |
FaceValue | 2 | |
Company Profile | ||
Metropolis Healthcare is engaged in the business of providing pathology and related healthcare services. The profile comprises of a variety of test combinations which are specific to a disease or disorder as well as wellness profiles that are used for health and fitness screening. It classifies its tests into ‘routine' tests such as blood chemistry analyses, blood cell counts and urine examination; ‘semi-specialized' tests such as thyroid function tests, viral and bacterial cultures, histology, cytology and infectious disease tests; and ‘specialized' tests such as tests for coagulation studies, autoimmunity tests, cytogenetics and molecular diagnostics. It is focused on providing reliable test results as well as value-added services such as home collection of specimens and online access to test reports. It also offers customized wellness packages to its institutional customers as per their requirement. |
1 Day |
|
+0.12% |
1 Week |
|
-0.70% |
1 Month |
|
-1.91% |
3 Month |
|
-21.70% |
6 Month |
|
-14.25% |
1 Year |
|
-46.99% |
2 Year |
|
-37.99% |
5 Year |
|
|
10 Year |
|
8 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 18.77 | 26.16 | 36.47 | 30.38 | 30.17 | 27.33 | 30.07 | 27.31 | |
Return on Capital Employed (%) | 27.47 | 40.06 | 54.28 | 45.22 | 45.10 | 37.90 | 41.60 | 34.39 | |
Return on Assets (%) | 14.48 | 19.06 | 23.75 | 16.93 | 15.51 | 14.78 | 18.43 | 16.19 |
Particulars | 9 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 361 | 265 | 323 | 415 | 419 | 524 | 707 | 886 | 957 | |
Non Curr. Liab. | 10 | 1 | 16 | 148 | 142 | 195 | 111 | 362 | 254 | |
Curr. Liab. | 75 | 105 | 152 | 233 | 241 | 210 | 240 | 342 | 289 | |
Minority Int. | 23 | 20 | 21 | 14 | 1 | 2 | 1 | 2 | 2 | |
Equity & Liab. | 468 | 391 | 512 | 810 | 803 | 930 | 1,059 | 1,593 | 1,502 | |
Non Curr. Assets | 167 | 166 | 227 | 367 | 381 | 492 | 415 | 1,159 | 1,177 | |
Curr. Assets | 302 | 225 | 285 | 443 | 422 | 438 | 645 | 434 | 326 | |
Misc. Exp. not W/O | ||||||||||
Total Assets | 468 | 391 | 512 | 810 | 803 | 930 | 1,059 | 1,593 | 1,502 |
Particulars | 9 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
Net Sales | 455 | 524 | 545 | 647 | 761 | 856 | 998 | 1,228 | 1,179 | |
Other Income | 6 | 22 | 26 | 8 | 8 | 9 | 12 | 18 | 16 | |
Total Income | 461 | 546 | 570 | 655 | 769 | 865 | 1,010 | 1,246 | 1,195 | |
Total Expenditure | -337 | -388 | -391 | -469 | -557 | -619 | -708 | -880 | -881 | |
PBIDT | 124 | 158 | 179 | 186 | 212 | 246 | 302 | 366 | 313 | |
Interest | -2 | -2 | -2 | -4 | -4 | -13 | -12 | -25 | -26 | |
Depreciation | -21 | -21 | -17 | -19 | -20 | -39 | -46 | -63 | -78 | |
Taxation | -33 | -46 | -53 | -52 | -63 | -41 | -61 | -79 | -55 | |
Exceptional Items | -8 | -25 | 16 | |||||||
PAT | 68 | 82 | 107 | 112 | 125 | 128 | 183 | 215 | 155 | |
Minority Interest | -7 | -8 | -8 | -3 | 0 | 0 | -1 | -1 | ||
Share Associate | -6 | -1 | -1 | |||||||
Other Related Items | ||||||||||
Consolidated Net Profit | 61 | 74 | 102 | 104 | 120 | 127 | 183 | 214 | 155 | |
Adjusted EPS | 62 | 77 | 107 | 109 | 24 | 25 | 36 | 42 | 30 |
Particulars | 6 years | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 102 | 104 | 90 | 215 | 249 | 253 | |
Cash Fr. Inv. | -86 | 2 | 35 | -105 | 62 | -738 | |
Cash Fr. Finan. | -17 | -87 | -118 | -55 | -33 | 163 | |
Net Change | -1 | 19 | 7 | 55 | 278 | -322 | |
Cash & Cash Eqvt | 26 | 43 | 51 | 107 | 387 | 66 |
Mon, 23 Jan 2023
Intimation W.R.T Withdrawal Of Petition Filed By Operational Creditors Pursuant to Point No.16(c) of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and as per the direction given by National Stock Exchange of India Limited (NSE) this is to inform you that the matter listed with National Company Law Tribunal Mumbai Bench Court -II (NCLT) namely Mr. Vinod Lath v/s Metropolis Healthcare Ltd and Dr. Bharat Gupta v/s M/s. Metropolis Healthcare Limited were amicably settled between the parties. Consequently the above-mentioned petitions have been withdrawn by respective petitioners and the said petitions have been disposed off by NCLT. The withdrawal order of NCLT is attached for your ready reference. Further please note that the Company is awaiting for certified copy of the said orders |
Thu, 12 Jan 2023
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 We enclosed herewith the Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for quarter ended December 31 2022 received from Link Intime India Private Limited Registrar & Share Transfer Agent of the Company. |
Sun, 08 Jan 2023
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS The Nomination and Remuneration Committee of the Board of the Directors of the Company vide circular resolution dated January 07 2023 have approved the allotment of 4 372 (Four Thousand Three Hundred and Seventy-Two) Equity shares of Rs.2/- (Rupees Two Only) each at an exercise price of Rs. 2/- (Rupees Two Only) each aggregating to Rs. 8 744 (Rupees Eight Thousand Seven Hundred and Forty-Four Only) against the Restrictive Stock Units (RSU) vested in and exercised by the employees of the Company under the MHL- Restrictive Stock Unit Plan 2020. |
Wed, 25 Jan 2023 |
|
|
|
|
|